Phase 3
Completed N=302
The Vaginal Health Trial
Atrophy of Vagina · Menopause · Dyspareunia (Female)
Source: ClinicalTrials.gov NCT02516202 ↗
Enrolled (actual)
302
Serious AEs
1.7%
Results posted
Jul 2018
Primary outcomePrimary: Most Bothersome Symptom (MBS) Severity — -1.2; -1.0; -0.2; -1.4 units on a scale — p=0.25
◆ Published Evidence
Established
57citations · ~11 / year
Association between postmenopausal vulvovaginal discomfort, vaginal microbiota, and mucosal inflammation.
Summary
This is a new application from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) Clinical Trials network. Here we propose to conduct a large multicenter trial comparing two common treatments, a vaginal hormone tablet and an over-the-counter gel, with placebo to evaluate their effects on bothersome vaginal symptoms and sexual function, and to create a biorepository of specimens for future translational, mechanistic research on the etiology of vaginal symptoms.
Linked Publications (5)
-
Association between postmenopausal vulvovaginal discomfort, vaginal microbiota, and mucosal inflammation.
-
Impact of Topical Interventions on the Vaginal Microbiota and Metabolome in Postmenopausal Women: A Secondary Analysis of a Randomized Clinical Trial.
-
Association of Vaginal Estradiol Tablet With Serum Estrogen Levels in Women Who Are Postmenopausal: Secondary Analysis of a Randomized Clinical Trial.
-
The complexity of genitourinary syndrome of menopause: number, severity, and frequency of vulvovaginal discomfort symptoms in women enrolled in a randomized trial evaluating treatment for genitourinary syndrome of menopause.
-
Comparison of the Vaginal Microbiota in Postmenopausal Black and White Women.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Most Bothersome Symptom (MBS) Severity |
-1.2; -1.0; -0.2; -1.4; -1.2; -1.3 | 0.25 |
| SECONDARY Vaginal Symptoms Index |
-0.7; -0.5; -0.6; -0.9; -0.7; -0.9 | 0.99 |
| SECONDARY Female Sexual Function Index |
3.1; 2.9; 3.2; 5.4; 3.1; 4.5 | 0.64 |
| SECONDARY Treatment Satisfaction |
8.6; 7.7; 8.1 | — |
| SECONDARY Patient Benefit Evaluation |
79; 58; 62; 20; 41; 34 | 0.02 sig |
| SECONDARY pH |
42; 77; 74; 36; 8; 10 | <0.001 sig |
| SECONDARY Vaginal Maturation Index |
34; 65; 63; 45; 8; 8 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Females aged 45-70 years
- 2 or more years since last natural menstrual period, or surgical menopause (bilateral oophorectomy)
- At least 1 vaginal symptom (inside or outside the vagina) reported from the following list, experienced in the past 30 days which is moderate or severe:
- Dryness at least once a week
- Itching at least once a week
- Irritation at least once a week
- Soreness/Pain at least once a week
- Pain associated with sexual activity at least once
- Signed informed consent
Exclusion Criteria
- Current unexplained abnormal genital bleeding (or any unevaluated bleeding since menopause)
- Currently pregnant, attempting pregnancy or breast feeding
- Current acute vaginal infection (as indicated by wet mount at V1)
- Pelvic or vaginal surgery in prior 60 days
- Antibiotic use in the past 30 days
- Women under age 55 with endometrial ablation
- Women under age 55 with hysterectomy and at least one ovary
- Current cancer treatment (exception basal or squamous skin cell cancers)
- Current or past thromboembolic disease (pulmonary embolus or deep vein thrombosis, not including thrombophlebitis), myocardial infarction or stroke
- Current severe liver disease
- Current or past breast or endometrial cancer or pre-cancer
- Blood clotting disorder (e.g., Factor V Leiden, prothrombin mutation, protein C, protein or antithrombin deficiency)
- Porphyria
- Current or past lichen sclerosus or lichen planus
- History of adverse reaction to vaginal estrogen or Replens
- Use of any systemic reproductive hormones (hormonal contraception, postmenopausal hormone therapies, SERMS) in the past 2 months
- Use of hormonal contraception in the past year
- Use of any type of vaginal estrogen product (however interested women will be allowed to join the study if they abstain from use during the month preceding enrollment)
- Use of any type of vaginal moisturizer, douche, vaginal prebiotic or probiotic, or soap in the vagina in the past month (however interested women will be allowed to join the study if they abstain from use during the month preceding enrollment)
- Unwilling to abstain from use of any non-study vaginal moisturizer, vaginal estrogen, douche, or soap in the vagina throughout the trial
- Unable to follow instructions, complete questionnaires, or physically unable to place product in the vagina
- Current participation in another drug trial or intervention study
- Chronic vulvo-vaginal symptoms in the 5 years before menopause (defined as a vaginal or vulvar condition requiring more than 4 visits to a health care provider in a given year)
Data sourced from ClinicalTrials.gov (NCT02516202) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.